{"id":390928,"date":"2017-08-17T00:00:00","date_gmt":"2017-08-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecv0004-2017-biopharma-acute-coronary-syndrome-access-and-reimbursement-accountable-care-organizations-us-2017\/"},"modified":"2026-05-05T23:28:58","modified_gmt":"2026-05-05T23:28:58","slug":"acrecv0004-2017-biopharma-acute-coronary-syndrome-access-and-reimbursement-accountable-care-organizations-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecv0004-2017-biopharma-acute-coronary-syndrome-access-and-reimbursement-accountable-care-organizations-us-2017\/","title":{"rendered":"Acute Coronary Syndrome | Access and Reimbursement | Accountable Care Organizations | US | 2017"},"content":{"rendered":"<p><strong>Introduction: <\/strong>This research explores the reimbursement and utilization landscape for acute coronary syndrome (ACS) drugs and the impact of accountable care organizations (ACOs) on payers\u2019 and cardiologists\u2019 decision-making. ACOs are provider organizations that manage the full continuum of care and take accountability for the total costs and quality of care for a defined patient population. ACS is a condition whose treatment can benefit from the integrated, patient-centered, evidence-based care practiced within ACOs and for which the goal of cost-effective treatment can influence prescribing.<\/p>\n<p><strong>Questions Answered in This Report:<\/strong><\/p>\n<ul>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E-->Generic clopidogrel dominates antiplatelet treatment of ACS, but Brilinta\u2019s superior clinical profile has helped it gain patient share despite its higher price and greater restrictions. <strong>How is prescribing different for ACS in the ACO environment? How do cardiologists regard the various agents? How do MCO restrictions affect utilization?<\/strong><\/li>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E-->Two relatively new PCSK9 inhibitors\u2014Repatha and Praluent\u2014will probably have their labels expanded to secondary prevention of ACS. <strong>What is their use currently in this indication? How are MCOs likely to cover these drugs for this indication? Which of them is likely to have an advantage?<\/strong><\/li>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E-->ACOs are expected to take on more risk in terms of the medical and pharmacy costs of their patients. <strong>What formularies do ACO physicians commonly use for ACS patients? When do MCOs expect to require ACOs to take on risk? How many ACOs have their own dedicated formularies?<\/strong><\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<ul>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E--><strong>Markets covered: <\/strong>United States.<\/li>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E--><strong>Methodology:<\/strong> Surveys of 100 cardiologists and 30 managed care organization (MCO) officials, including 14 pharmacy directors and 16 medical directors, in January 2017.<\/li>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E--><strong>Indication coverage:<\/strong> Acute coronary syndrome (ACS).<\/li>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E--><strong>Key Drugs covered<\/strong>: Brilinta, clopidogrel, Effient, Plavix, Praluent, Repatha, Vascepa, Zontivity.<\/li>\n<li><!--{C}%3C!%2D%2D%5Bif%20!supportLists%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bendif%5D%2D%2D%3E--><strong>Key companies mentioned<\/strong>: \u00a0Amgen, AstraZeneca, Eli Lilly, Merck, Sanofi.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390928","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-coronary-syndrome","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390928\/revisions"}],"predecessor-version":[{"id":394052,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390928\/revisions\/394052"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}